
CareDx, Inc
CDNA
Updated: 24/09/2026, 14:56:12
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
No summaries found.
- Share price
- $54.31
- Market cap
- $2.81B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- John Walter Hanna Jr.
- Employees
- 763
- IPO date
- 17/07/2014
- Beta
- 2.43
- Last dividend
- $0.00
- Day range
- $54.00 – $57.16
- 52-week range
- $13.95 – $57.16
- 1-day performance
- -3.86%
- 1-year performance
- 289.32%
- Current drawdown (1Y)
- -4.99%
- CIK
- 0001217234
- CUSIP
- 14167L103
- ISIN
- US14167L1035
- Created
- 07/12/2025, 03:14:21
- Last update
- 24/09/2026, 14:56:12
Track CareDx, Inc with an AI analyst
See which prediction-market events move CDNA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
MarketBeat • STOCK • 08/06/2026, 22:04:32
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 18:38:29
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
MarketBeat • STOCK • 07/06/2026, 08:04:47
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 04/05/2026, 09:43:24
CareDx Launches AlloSeq Nano for High-Resolution Rapid HLA Typing
Zacks Investment Research • STOCK • 21/04/2026, 14:42:20
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
Business Wire • STOCK • 20/04/2026, 09:05:00
All You Need to Know About CareDx (CDNA) Rating Upgrade to Buy
Zacks Investment Research • STOCK • 17/04/2026, 15:00:57
CareDx Sharpens Focus On Core Testing Services
Benzinga • STOCK • 16/04/2026, 16:37:19
Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division
GlobeNewsWire • STOCK • 16/04/2026, 04:00:00
CareDx Introduces VANTx AI Platform for Complex Transplant Datasets
Zacks Investment Research • STOCK • 12/03/2026, 13:16:06
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 25/02/2026, 02:27:57
CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks Investment Research • STOCK • 24/02/2026, 22:00:58